Histone methylation in myelodysplastic syndromes

被引:0
|
作者
Wei, Yue [1 ]
Ganan-Gomez, Irene [1 ,2 ]
Salazar-Dimicoli, Sophie [1 ]
McCay, Sara L. [1 ]
Garcia-Manero, Guillermo [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Alcala De Henares, Dept Biochem & Mol Biol, Madrid 28871, Spain
关键词
histone demethylase inhibitor; histone methylation; histone methyltransferase; myelodysplastic syndrome; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DEACETYLASE INHIBITOR; LYSINE METHYLATION; METHYLTRANSFERASE ACTIVITY; DEMETHYLASE INHIBITORS; H3K4; TRIMETHYLATION; STRUCTURAL BASIS; DNA METHYLATION;
D O I
10.2217/EPI.11.9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Histone methylation is a type of epigenetic modification that is critical for the regulation of gene expression. Numerous studies have demonstrated that abnormalities of this newly characterized epigenetic modification are involved in the development of multiple diseases, including cancer. There is also emerging evidence for a link between histone methylation and the pathogenesis of myeloid neoplasms, including myelodysplastic syndromes (MDS). This article provides an overview of recent progress in the studies of histone methylation in myeloid malignancies, with an emphasis on MDS. We cover each type of histone methylation modification and their regulatory mechanisms, as well as their abnormalities in MDS or potential connections to MDS. We also summarize the recent progress in the development of inhibitors targeting histone methylation and their applications as potential therapeutic agents.
引用
收藏
页码:193 / 205
页数:13
相关论文
共 50 条
  • [21] Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes
    Benetatos, Leonidas
    Vartholomatos, George
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2018, 75 (11) : 1999 - 2009
  • [22] DAPK AND TRAIL RECEPTORS METHYLATION STATUS IN MYELODYSPLASTIC SYNDROMES PATIENTS
    Cortesao, E.
    Jorge, J.
    Goncalves, A. C.
    Pires, A.
    Alves, R.
    Mocho, C.
    Rito, L.
    Magalhaes, E.
    Carda, J. P.
    Geraldes, C.
    Espadana, A. I.
    Pereira, A.
    Ribeiro, L.
    Nascimento-Costa, J. M.
    Sarmento-Ribeiro, A. B.
    HAEMATOLOGICA, 2014, 99 : 94 - 94
  • [23] Do histone deacetylase inhibitors have a place in the treatment of myelodysplastic syndromes?
    Gore, S. D.
    LEUKEMIA RESEARCH, 2007, 31 : S21 - S21
  • [24] Promoter Methylation and Decreased Expression of Mir-124 In Myelodysplastic Syndromes
    Meng, Yuesheng
    Xia, Qiao
    Hu, Jun
    BLOOD, 2010, 116 (21) : 1636 - 1636
  • [25] MECHANISMS OF RESISTANCE TO THE HYPOMETHYLATING AGENT AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: FOCUS ON METHYLATION
    Brogi, A.
    Yang, Q.
    Masala, E.
    Figueroa, M.
    Santini, V.
    LEUKEMIA RESEARCH, 2021, 108 : S34 - S34
  • [26] DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
    Shen, Lanlan
    Kantarjian, Hagop
    Guo, Yi
    Lin, E.
    Shan, Jianqin
    Huang, Xuelin
    Berry, Donald
    Ahmed, Saira
    Zhu, Wei
    Pierce, Sherry
    Kondo, Yutaka
    Oki, Yasuhiro
    Jelinek, Jaroslav
    Saba, Hussain
    Estey, Eli
    Issa, Jean-Pierre J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) : 605 - 613
  • [27] SOX7 methylation is an independent prognostic factor in myelodysplastic syndromes
    Xu, Zi-jun
    Tang, Chun-yan
    Zhou, Jing-dong
    Ma, Ji-chun
    Wen, Xiang-mei
    Deng, Zhao-qun
    Leng, Jia-yan
    Qiu, Zhi-yuan
    Qian, Jun
    Lin, Jiang
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (02) : 322 - 328
  • [28] Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes
    Nagata, Yasunobu
    Suzuki, Hiromichi
    Grossmann, Vera
    Nagae, Genta
    Okuno, Yusuke
    Bacher, Ulrike
    Schnittger, Susanne
    Shiozawa, Yusuke
    Yoshizato, Tetsuichi
    Alpermann, Tamara
    Yoshida, Kenichi
    Kataoka, Keisuke
    Nadarajah, Niroshan
    Roller, Andreas
    Shiraishi, Yuichi
    Chiba, Kenichi
    Tanaka, Hiroko
    Kohlmann, Alexander
    Haferlach, Claudia
    Sato, Tsutomu
    Hirase, Chikara
    Dobashi, Nobuaki
    Kiguchi, Toru
    Chiba, Shigeru
    Ohtake, Shigeki
    Kiyoi, Hitoshi
    Kobayashi, Yukio
    Naoe, Tomoki
    Miyano, Satoru
    Kern, Wolfgang
    Makishima, Hideki
    Aburatani, Hiroyuki
    Miyazaki, Yasushi
    Haferlach, Torsten
    Ogawa, Seishi
    BLOOD, 2015, 126 (23)
  • [29] MECHANISMS OF RESISTANCE TO THE HYPOMETHYLATING AGENT AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: FOCUS ON METHYLATION
    Brogi, A.
    Yang, Q.
    Masala, E.
    Santini, V.
    Figueroa, M. E.
    HAEMATOLOGICA, 2021, 106 (10) : 28 - 29
  • [30] DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes
    Reilly, Brian
    Tanaka, Tiffany N.
    Diep, Dinh
    Yeerna, Huwate
    Tamayo, Pablo
    Zhang, Kun
    Bejar, Rafael
    BLOOD ADVANCES, 2019, 3 (19) : 2845 - 2858